Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

vTv Therapeutics Inc. (VTVT)

0.99   0.014 (1.41%) 01-27 15:58
Open: 0.95 Pre. Close: 0.9762
High: 1 Low: 0.95
Volume: 23,191 Market Cap: 81(M)

Technical analysis

as of: 2023-01-27 4:49:11 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 1.22     One year: 1.43
Support: Support1: 0.8    Support2: 0.64
Resistance: Resistance1: 1.04    Resistance2: 1.22
Pivot: 0.9
Moving Average: MA(5): 0.98     MA(20): 0.85
MA(100): 0.87     MA(250): 0.8
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 79     %D(3): 81.1
RSI: RSI(14): 72.4
52-week: High: 1.39  Low: 0.38
Average Vol(K): 3-Month: 70 (K)  10-Days: 79 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ VTVT ] has closed below upper band by 25.1%. Bollinger Bands are 47.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1 - 1.01 1.01 - 1.01
Low: 0.94 - 0.94 0.94 - 0.95
Close: 0.98 - 0.99 0.99 - 1

Company Description

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

Headline News

Fri, 27 Jan 2023
vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews ... - MarketBeat

Mon, 23 Jan 2023
Upcoming 2023 Hyundai Verna To Bring Back Excitement In Midsize Sedan Segment - GaadiWaadi.com

Mon, 23 Jan 2023
FY2023 Earnings Forecast for vTv Therapeutics Inc. (NASDAQ:VTVT ... - MarketBeat

Sat, 21 Jan 2023
StockNews.com has added vTv Therapeutics (NASDAQ:VTVT) to its ... - Best Stocks

Fri, 20 Jan 2023
vTv Therapeutics Investors Five-Year Losses Still 87%, Even After 21% Gain Last Week - Simply Wall St

Thu, 22 Dec 2022
7 Drug Stocks to Buy That Will Soar in 2023 - InvestorPlace

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 81 (M)
% Held by Insiders 2.606e+007 (%)
% Held by Institutions 64.4 (%)
Shares Short 1,080 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -2.561e+007
EPS Est Next Qtl 0.18
EPS Est This Year -1.06
EPS Est Next Year -2.25
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 273.8
Return on Equity (ttm) -48
Qtrly Rev. Growth 2.02e+006
Gross Profit (p.s.) -0.13
Sales Per Share 0.07
EBITDA (p.s.) -0.34
Qtrly Earnings Growth -0.3
Operating Cash Flow 0 (M)
Levered Free Cash Flow -16 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 13.2
Price to Cash Flow 5.98

Stock Dividends

Dividend 0
Forward Dividend 1.09e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.